RemeGen’s Telitacicept Gains Approval for Myasthenia Gravis Treatment in China

RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.

RemeGen Co., Ltd. announced that its drug Telitacicept has received marketing approval from the National Medical Products Administration in China for treating generalized myasthenia gravis. The approval follows successful phase III clinical trials demonstrating significant efficacy and safety, with Telitacicept outperforming placebo in improving patient symptoms. This approval is expected to address the unmet medical needs of myasthenia gravis patients in China and supports RemeGen’s ongoing efforts to validate the drug’s effectiveness globally.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative drugs. The company is involved in creating treatments for autoimmune diseases, with a market focus on conditions such as systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis.

Average Trading Volume: 9,419,229

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.81B

Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.